News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Crossbow Therapeutics, a biotech company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced a $80 million Series A funding round.
Japan’s Ministry of Health, Labour, and Welfare approved FluMist Quadrivalent in March 2023, marking the first approval of an intranasal vaccine in the country’s history.
Science and technology company Merck has announced the expansion of its facility in Lenexa, Kansas, USA, adding 9,100 sq m2 of lab space and production capability to manufacture cell culture media.